Martin Meglasson - Net Worth and Insider Trading

Martin Meglasson Net Worth

The estimated net worth of Martin Meglasson is at least $2 Million dollars as of 2024-11-13. Martin Meglasson is the V-P, Discovery Research of Ligand Pharmaceuticals Inc and owns about 17,042 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $2 Million. Martin Meglasson is also the Chief Scientific Officer of Bellerophon Therapeutics Inc and owns about 1,273 shares of Bellerophon Therapeutics Inc (BLPH) stock worth over $47. Details can be seen in Martin Meglasson's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Martin Meglasson has not made any transactions after 2015-05-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Martin Meglasson

To

Martin Meglasson Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Martin Meglasson owns 2 companies in total, including Bellerophon Therapeutics Inc (BLPH) , and Ligand Pharmaceuticals Inc (LGND) .

Click here to see the complete history of Martin Meglasson’s form 4 insider trades.

Insider Ownership Summary of Martin Meglasson

Ticker Comapny Transaction Date Type of Owner
BLPH Bellerophon Therapeutics Inc 2015-05-20 Chief Scientific Officer
LGND Ligand Pharmaceuticals Inc 2010-05-11 V-P & Discovery Research

Martin Meglasson Latest Holdings Summary

Martin Meglasson currently owns a total of 2 stocks. Among these stocks, Martin Meglasson owns 17,042 shares of Ligand Pharmaceuticals Inc (LGND) as of May 11, 2010, with a value of $2 Million and a weighting of 100%. Martin Meglasson also owns 1,273 shares of Bellerophon Therapeutics Inc (BLPH) as of May 20, 2015, with a value of $47 and a weighting of 0%.

Latest Holdings of Martin Meglasson

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
LGND Ligand Pharmaceuticals Inc 2010-05-11 17,042 120.74 2,057,651
BLPH Bellerophon Therapeutics Inc 2015-05-20 1,273 0.04 47

Holding Weightings of Martin Meglasson


Martin Meglasson Form 4 Trading Tracker

According to the SEC Form 4 filings, Martin Meglasson has made a total of 0 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 1,042 shares on May 11, 2010, which cost Martin Meglasson around $10,188.

According to the SEC Form 4 filings, Martin Meglasson has made a total of 0 transactions in Bellerophon Therapeutics Inc (BLPH) over the past 5 years. The most-recent trade in Bellerophon Therapeutics Inc is the acquisition of 47 shares on May 20, 2015, which cost Martin Meglasson around $5,981.

Insider Trading History of Martin Meglasson

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Martin Meglasson Trading Performance

GuruFocus tracks the stock performance after each of Martin Meglasson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Martin Meglasson is -8.18%. GuruFocus also compares Martin Meglasson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Martin Meglasson within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Martin Meglasson's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Martin Meglasson

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -1.46 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -1.01 LIMIT LIMIT LIMIT LIMIT LIMIT

Martin Meglasson Ownership Network

Ownership Network List of Martin Meglasson

No Data

Ownership Network Relation of Martin Meglasson

Insider Network Chart

Martin Meglasson Owned Company Details

What does Bellerophon Therapeutics Inc do?

Who are the key executives at Bellerophon Therapeutics Inc?

Martin Meglasson is the Chief Scientific Officer of Bellerophon Therapeutics Inc. Other key executives at Bellerophon Therapeutics Inc include 10 percent owner Puissance Life Science Opportunities Fund Vi , VP of Business Operations Parag Suresh Shah , and See Remarks Martin Dekker .

Bellerophon Therapeutics Inc (BLPH) Insider Trades Summary

Over the past 18 months, Martin Meglasson made no insider transaction in Bellerophon Therapeutics Inc (BLPH). Other recent insider transactions involving Bellerophon Therapeutics Inc (BLPH) include a net sale of 694,421 shares made by Puissance Capital Fund (gp) Llc , a net sale of 1,076,841 shares made by Puissance Life Science Opportunities Fund Vi , and a net sale of 9,455 shares made by Bobae Kim .

In summary, during the past 3 months, insiders sold 0 shares of Bellerophon Therapeutics Inc (BLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,780,717 shares of Bellerophon Therapeutics Inc (BLPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,780,717 shares.

Bellerophon Therapeutics Inc (BLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Bellerophon Therapeutics Inc Insider Transactions

No Available Data

Martin Meglasson Mailing Address

Above is the net worth, insider trading, and ownership report for Martin Meglasson. You might contact Martin Meglasson via mailing address: 53 Frontage Road, Suite 301, Hampton Nj 08827.